Spaulding Clinical Research Awarded Five-Year Contract With FDA

Spaulding Clinical Research today announced that it has been awarded a five-year contract with the U.S. Food and Drug Administration (FDA) Division of Applied Regulatory Science to conduct multiple clinical trials in various therapeutic areas of interest.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, February 27, 2020
Information
Tags: 
FDA, Other Health, Stem cells, Pharmaceutical, Oncology, Medical devices, Infectious diseases, Hospitals, Clinical trials, Cardiology, Biotechnology, Science, Other Science, Research, Health, Medical Supplies, Health, Articles, Medical research, Pharmaceutical industry, Design of experiments, Food and Drug Administration, Clinical trial, Clinical research, Clinical research coordinator, Outline of clinical research
Geotags: 
United States, Wisconsin
⚠generated by AI ↴
Summary
Key Points: 
  • Spaulding Clinical Research today announced that it has been awarded a five-year contract with the U.S. Food and Drug Administration (FDA) Division of Applied Regulatory Science to conduct multiple clinical trials in various therapeutic areas of interest.
  • Spaulding Clinical is responsible for conducting the trials and providing the necessary support services including clinical trial recruitment, conduct, and laboratory assessments.
  • Spaulding Clinical is perfectly suited to conduct these trials as we have the right-sized project management and principal investigator team that will be able to give the FDA office the attention they need, said Cassandra Erato , CEO at Spaulding Clinical Research.
  • Spaulding Clinical has been working with the U.S. government on clinical trials over the past seven years.


Spaulding Clinical Research today announced that it has been awarded a five-year contract with the U.S. Food and Drug Administration (FDA) Division of Applied Regulatory Science to conduct multiple clinical trials in various therapeutic areas of interest. They have kicked off this agreement with $5 million of clinical trial work to be run in 2020. Spaulding Clinical is responsible for conducting the trials and providing the necessary support services including clinical trial recruitment, conduct, and laboratory assessments.

The objectives of each trial vary considerably among different therapeutic areas, but all address important regulatory science questions in today’s pharmaceutical market.

“We are happy to partner with the FDA to help address agency questions about various classes of drugs. Spaulding Clinical is perfectly suited to conduct these trials as we have the right-sized project management and principal investigator team that will be able to give the FDA office the attention they need,” said Cassandra Erato, CEO at Spaulding Clinical Research.

Spaulding Clinical has been working with the U.S. government on clinical trials over the past seven years. “We began conducting clinical trials for the FDA to explore a model to screen new drugs for prolongation of QT. Through this work and resulting publications, we have developed a productive partnership,” said Dr. Jay Mason, chief medical officer at Spaulding Clinical Research.

About Spaulding Clinical Research

Spaulding Clinical opened in 2008 and was built upon fully electronic data and integrated, purposefully engineered systems for conducting Phase 1 trials. Spaulding runs a 200-bed facility in West Bend, Wisconsin, and conducts and analyzes First-in-Human, clinical Proof-of-Concept, cardiovascular safety (TQT, concentration effect), and NDA-enabling clinical pharmacology studies. Spaulding Clinical provides expertise on study design, medical writing, clinical data management, biostatistics, and PK/PD analysis. Learn more at spauldingclinical.com.

Copyright: 
Copyright Business Wire 2020